TEDA International Cardiovascular Hospital

St. Joseph's Hospital Named One of the Nation's 50 Top Cardiovascular Hospitals by Fortune and PINC AI™

Retrieved on: 
목요일, 3월 16, 2023

TAMPA, Fla., March 15, 2023 /PRNewswire/ -- Today, St. Joseph's Hospital was named one of the nation's 50 Top Cardiovascular Hospitals™ according to an independent quality analysis provided by PINC AI™ and reported by Fortune .

Key Points: 
  • TAMPA, Fla., March 15, 2023 /PRNewswire/ -- Today, St. Joseph's Hospital was named one of the nation's 50 Top Cardiovascular Hospitals™ according to an independent quality analysis provided by PINC AI™ and reported by Fortune .
  • This is the fifth time and third consecutive year St. Joseph's Hospital in Tampa has made this prestigious list.
  • "At St. Joseph's Hospital, we continually pursue clinical excellence provided by compassionate caregivers," said Kimberly Guy, co-chief operating officer of BayCare.
  • This year, the 50 Top Cardiovascular Hospitals™ program winners had better results on indicators intended to measure clinical outcomes, operational efficiency, financial performance and patient experience.

Halifax Health Selects BPAS for Retirement Plan Services

Retrieved on: 
화요일, 11월 1, 2022

"BPAS is honored to service the Halifax suite of defined contribution plans," said Elizabeth Kaido, Senior Vice President of Sales at BPAS.

Key Points: 
  • "BPAS is honored to service the Halifax suite of defined contribution plans," said Elizabeth Kaido, Senior Vice President of Sales at BPAS.
  • We're also confident that Halifax Health plan participants will get a lot of value from our new BPAS participant website and robust education and wellness tools."
  • The BPAS family of services includes Workplace Retirement Plans, Actuarial & Pension, Healthcare Consulting, IRA, VEBA HRA, Health & Welfare Plans, Fiduciary, Collective Investment Funds, Fund Administration, and Institutional Trust.
  • The BPAS Actuarial & Pension Services division has served as actuary and consultant on the Halifax Health defined benefit (DB) plans for more than 10 years.

BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Retrieved on: 
월요일, 3월 28, 2022

Acoramidis is currently being evaluated in Phase 2 and Phase 3 studies in patients with ATTR.

Key Points: 
  • Acoramidis is currently being evaluated in Phase 2 and Phase 3 studies in patients with ATTR.
  • When the transthyretin (TTR) becomes unstable due to inherited variants or aging, it can accumulate as amyloid fibrils in various organs in the body, causing ATTR.
  • TTR amyloid deposits predominantly in the heart and/or peripheral nerves, causing cardiomyopathy (ATTR-CM) and/or polyneuropathy (ATTR-PN).
  • Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time.